CytoSorbents, headquartered in Princeton, New Jersey, specializes in blood purification technology and critical care immunotherapy, employing 186 people since its IPO on June 17, 2005. Its flagship product, CytoSorb, addresses cytokine storms in critical illnesses, with additional products like VetResQ and various candidates under development.
Cytosorbents (CTSO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cytosorbents's actual EPS was -$0.02, beating the estimate of -$0.07 per share, resulting in a 71.99% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
